乾燥血液スポット（DBS）バイオマーカーによる神経変性の神経変性バイオマーカーが、大規模集団ベースのサンプルで7年先の認知低下と認知症を予測する

It is unknown whether biomarkers of neurodegeneration collected from dried blood spots (DBS) in large-scale population settings are useful in predicting cognitive decline many years later.

In 2015, we collected DBS of 13,679 individuals aged 58 and older. All DBS were assayed for ApoE4 protein, and a smaller subsample for pTau217, GFAP, and NfL. In 2022, we obtained detailed cognition measures for 6,523 respondents. Regression analyses tested the likelihood of cognitive impairment as a function of biomarker levels.

Respondents with ApoE4 detection have worse cognitive performance seven years later as measured by six different cognitive performance measures (p<0.001). The combination of all four biomarkers is a statistically significant predictor for five cognitive performance measures, with pTau217 having the most systematic association.

DBS-based biomarkers of neurodegeneration provide a cost-efficient and scalable early warning signal enabling preventive measures against AD/ADRD before the onset of serious symptoms.